期刊文献+

难治性或复发性白血病治疗进展 被引量:1

下载PDF
导出
出处 《山东医药》 CAS 北大核心 2002年第6期61-63,共3页 Shandong Medical Journal
  • 相关文献

参考文献13

  • 1[1]Cortes J,Estey E,Beran M,et al.Cyclophosphamide,Ara-C and Topotecan (CAT)for patients with refractory or rep lased acute leukemia.Leuk Lymphoma,2000, 36(5~6):479~484.
  • 2[2]Cortes J,Estery E,Brien S,et al.Highd ose liposomal dauno rubicin and highdose cytarabine combina tion in patients with refractory or repl ased acute myelogenous leukemia.Cancer,2 001,92(1):7~14.
  • 3[3]Sternberg DW,Aird W,Neuberg D,et al.Re treatment of patients with recurrent and primary refractory acute myelogenous le ukemia using mitoxantrone and intermedia tedose cytarabine:a pharma-cologically ba s ed regimen.Cancer,2000,88(9):2037~2041.
  • 4[4]Karanes C,Kopecky KJ,Head DR,et al.A p hase Ⅲ comparison of high dose Ara-C(HID AC)versus HIDAC plus mitoxantrone in the treatment of first replased or refracto ry acute myeloid leukemia.Leuk Res,1999, 23(9):787~794.
  • 5[5]Vidarsson B,A bonour R,Williams EC,et al.Asequence therapy of fludarabine with cytarabine in refractory AML.Leuk Lymph oma,2001,41(3~4)321~331.
  • 6[6]Jackson G,Taylor P,Smith GM,et al.A mu lticentre,non-comparative phase Ⅱ study of a combination of fludarabine p hosphate,cytarabine and granulocyte colo ny stimulating factor in replased and re fractory acute myeloid leukemia and de n ovo refractory anemia with excess of bla sts in transformation.Br J Haematol,2001 ,112(1):127~137.
  • 7[7]Bassan R,Lerede T,Buelli M,et al.A new combination of carboplatin,high-dose cy tarabie and cross-over mitoxantrone or i darubicin for refractory and relapsed ac ute myeloid leukemia.Haematologica,1998, 83(5):422~427.
  • 8[8]Ferra C,Berlanga JJ,Callardo D,et al.M itoxantrone,etoposide,carboplatnum and a ra-C combination therapy (MECA) in refrac tory and replased acute leukemia.Leuk Ly mphoma,2000,39(5~6):583~590
  • 9[9]Tricot G.Weber G Biochemically targete d therapy of r efractory leukemia and myeloid blast cri sis of chronic granulocytic leukemia wit h tiazofurin,a selective blocker of inos ine 5-phosphate dehydrogenase activity.A nticancer Res,1996,16(6A):3341~3347.
  • 10[10]Robak T,Wrzesien Kus A,Lech Mara nda E,et al.Combination regimen of cladri bine(2-chlorodeoxyadenosine),cytarabine and G~CSF(CLAG) as induction therapy for patients with replased or refractory ac ute myeloid lrukemia leuk.Lymphoma,2000, 39(1~2):121~129.

同被引文献3

  • 1第二届全国难治性白血病研讨会 关于难治性白血病诊断标准的建议(草案)[J].白血病,2000,9(1):63-63.
  • 2Sternberg DW, Aird W, Neuberg D. et al. Retreatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitorantrone and intermediatedose cytambine : a pharmacologically based regimen [ J ] . Cancer,2000,88(9) : 2037-2041.
  • 3吴结红,林东军.MA方案治疗难治性复发性急性非淋巴细胞白血病临床观察[J].广东医学,2002,23(6):650-651. 被引量:3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部